Gastricand Esophageal Cancer Drugs Market, by Therapy Type (Chemotherapy, TargetedTherapy, and Immunotherapy), by Disease Condition (Adenocarcinomas,Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, andOthers), by Distribution Channel (Hospital, Retail Pharmacy, and OnlinePharmacy), and by Geography (North America, Europe, Asia Pacific, LatinAmerica, Middle East, and Africa) - Size, Share, Outlook, and OpportunityAnalysis 2018 – 2026
Gastric and esophageal cancersare characterized by growth of malignant (cancerous) cells, forming a tumor,within the lining of stomach and esophagus. Smoking, excessive alcoholconsumption, and Barrett’s esophagus can causes gastric and esophageal cancers.Symptoms of gastric and esophageal cancers include difficulty in swallowing(dysphagia), weight loss, chest pain, indigestion or heartburn, coughing orhoarseness, pain behind the breastbone. Early stage of gastric and esophagealcancer does not show any of this signs and symptoms.
Gastric and Esophageal CancerDrugs Market- Drivers
Increasing number of cancer drugsin pipeline studies and rising involvement of key players for development ofcancer treatment are expected to propel gastric and esophageal cancer drugsmarket growth. For instance, in April 2016, Centre Hospitalier Universitaire deBesancon, initiated Phase 1 and Phase 2 clinical trial for Carboplatin todetermine the maximum tolerated dose (MTD) and recommended doses for phase II(RP2D) by considering the treatment scheme of Dutch study for chemotherapy andradiotherapy. The study is conducted in elderly patients with esophagus cancer.Carboplatin is an anticancer chemotherapy drug from alkylating agent category.The study is estimated to complete by April 2024.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2438
Moreover, in February 2017, HenanCancer Hospital in collaboration with Jiangsu HengRui Medicine Co., Ltd.,initiated Phase 2 exploratory clinical trial to evaluate the efficacy ofApatinib, treatment for advanced esophagus cancer. Apatinib is a tyrosine kinaseinhibitor that selectively inhibits the vascular endothelial growth factorreceptor-2(VEGFR2).
However, high cost of therapy forthe treatment of gastric and esophageal cancers is expected to restraint themarket growth. For instance, as per the report published in Healthday, in 2013,cancer patients paid US$ 207,000 a year for the treatment and medications whilein 1995 the cost was US$ 54,100 a year.
Gastric and Esophageal Cancer DrugsMarket- Regional Analysis
On the basis of region, theglobal gastric and esophageal cancer drugs market is segmented into NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America isexpected to be the leading region in the gastric and esophageal cancer drugsmarket during the forecast period, owing to high prevalence of esophagealcancer in this region. For instance, the American Cancer Society’s estimatedthat about 17,650 new esophageal cancer cases in the U.S. will be diagnosed(13,750 in men and 3,900 in women) by 2019. Moreover, mergers and acquisitionsactivities by key players in this region are expected to propel the marketgrowth during the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/gastric-and-esophageal-cancer-drugs-market-2438
For instance, in December 2018,GlaxoSmithKline plc announced the acquisition of TESARO Inc, an oncologyfocused company based in Massachusetts, U.S. This acquisition is expected tostrengthen GSK’s pharmaceutical business by accelerating GSK’s pipeline and commercialcapability in oncology.
Key players in Europe are focusedon various business strategies such as acquisitions and mergers, which in turnboosts growth of the market. For instance, in September 2018, BoehringerIngelheim acquired all shares of ViraTherapeutics, an Austria-basedbiopharmaceutical company, specializing in the development of oncolytic viraltherapies. The total transaction value for this acquisition was US$ 240.52million. This acquisition strengthened Boehringer Ingelheim’s commitment toresearch and development for viral-based immuno-oncology treatment.
Key players for gastric andesophageal cancer drugs market includes Amgen, Eli Lilly and Company, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH,Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson,Gilead Sciences, Merck & Co. and others.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2438
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
